Infective pneumonia represents a significant clinical challenge in IBD patients receiving TNF-α inhibitors, stemming from both disease-related immunosuppression and drug-induced alterations in immune response [8]. The gene discussed is TNF; the disease is susceptibility to pneumonia measurement.